MindMed Q3 net loss widens to $67.3 mln

Reuters

2025/11/07

MindMed Q3 net loss widens to $67.3 mln

Overview

MindMed Q3 net loss widens to $67.3 mln, driven by increased R&D and G&A expenses
Company completed public offering, raising $242.8 mln in net proceeds

Result Drivers

PUBLIC OFFERING - Completed public offering raised $242.8 mln in net proceeds, strengthening financial position

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.78
Q3 Net Income		-$67.3 mln
Q3 Basic EPS		-$0.78

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Mind Medicine (MindMed) Inc is $21.00, about 45.1% above its November 5 closing price of $11.53

Press Release: ID:nBw19QgRRa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581201074"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581201074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581201074?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581201074","market":"fut","top_or_hot":-1,"title":"MindMed Q3 net loss widens to $67.3 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>MindMed Q3 net loss widens to $67.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>MindMed Q3 net loss widens to $67.3 mln, driven by increased R&amp;D and G&amp;A expenses</p></li><li><p>Company completed public offering, raising $242.8 mln in net proceeds</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PUBLIC OFFERING - Completed public offering raised $242.8 mln in net proceeds, strengthening financial position</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$67.3 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed)</a> Inc is $21.00, about 45.1% above its November 5 closing price of $11.53</p></li></ul><p>Press Release: <span>ID:nBw19QgRRa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Q3 net loss widens to $67.3 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Q3 net loss widens to $67.3 mln\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>MindMed Q3 net loss widens to $67.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>MindMed Q3 net loss widens to $67.3 mln, driven by increased R&amp;D and G&amp;A expenses</p></li><li><p>Company completed public offering, raising $242.8 mln in net proceeds</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PUBLIC OFFERING - Completed public offering raised $242.8 mln in net proceeds, strengthening financial position</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$67.3 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed)</a> Inc is $21.00, about 45.1% above its November 5 closing price of $11.53</p></li></ul><p>Press Release: <span>ID:nBw19QgRRa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I4:1","article_id":"2581201074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581201074","pubTimestamp":1762463701,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MindMed Q3 net loss widens to $67.3 mlnOverviewMindMed Q3 net loss widens to $67.3 mln, driven by increased R&D and G&A expensesCompany completed public offering, raising $242.8 mln in net proceedsRes","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4547":"WSB热门概念"},"translate_title":"MindMed第三季度净亏损扩大至6730万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Q3 net loss widens to $67.3 mlnOverviewMindMed Q3 net loss widens to $67.3 mln, driven by increased R&D and G&A expensesCompany completed public offering, raising $242.8 mln in net proceedsResult DriversPUBLIC OFFERING - Completed public offering raised $242.8 mln in net proceeds, strengthening financial positionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.78Q3 Net Income-$67.3 mlnQ3 Basic EPS-$0.78Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Mind Medicine (MindMed) Inc is $21.00, about 45.1% above its November 5 closing price of $11.53Press Release: ID:nBw19QgRRaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}